key: cord-0729134-a95ak58h
authors: Picod, Adrien; Rebibou, Jean-Michel; Dossier, Antoine; Cador, Bérengère; Ribes, David; Vasco-Moynet, Claire; Stephan, Caroline; Bellal, Mathieu; Wynckel, Alain; Poullin, Pascale; Péju, Edwige; Ricard, Laure; Kahn, Jean-Emmanuel; Bouzid, Raïda; Benhamou, Ygal; Joly, Bérangère; Veyradier, Agnès; Coppo, Paul
title: Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination
date: 2022-03-12
journal: Blood
DOI: 10.1182/blood.2021015149
sha: 3621b3743c25d582e58ca99e82740909419ba4f3
doc_id: 729134
cord_uid: a95ak58h

nan

13. Service d'hématologie, Hôpital Saint-Antoine, Assistance publique -Hôpitaux de Paris, Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening 60 form of thrombotic microangiopathy which manifests by hemolytic anemia, consumptive 61 thrombocytopenia and diffuse microthrombi formation with organ damage resulting from a 62 severe immune-mediated ADAMTS13 deficiency (activity below 10%) 1 . Recently, several cases 63 of iTTP have been described after coronavirus disease 2019 (COVID-19) vaccination 2,3 . These 64 temporally associated events raise concerns about a potential causal link between vaccination 65 and the development of the disease. Consequently, uncertainties persist regarding the best 66 way to manage these cases as well as the approach to adopt in patients with known iTTP 67 regarding vaccination. Finally, certain similarities with vaccine-induced thrombotic 68 thrombocytopenia (VITT), a well-established complication of adenoviral vector-based 69 vaccination 4 , raise the question of the differential diagnosis between these two entities. 70

The French Reference Center for Thrombotic Microangiopathies is a national network 72 of French and French-speaking physicians involved in the diagnosis and care of patients with 73 thrombotic microangiopathies. To investigate a possible link between COVID-19 vaccination 74 and the occurrence of iTTP, all constitutive centers were asked to report cases of iTTP 75 occurring in the 30 days following vaccination. We considered all episodes (new-onset or 76 relapse) of iTTP following the first or subsequent doses of one of the four COVID-19 vaccines 77 licensed for use in France (BNT162b2 -Pfizer-BioNTEch, mRNA1273 -Moderna, ChAdOx1 78 nCoV-19 -AstraZeneca, Ad26.COV2.S -Janssen) occurring between December 2020 and 79

November 2021. As an exploratory analysis, the number of cases identified was compared to 80 the expected number of cases, estimated by considering the theoretical incidence of iTTP in France as well as the duration of post-vaccination follow-up truncated at 30-days for all 82 vaccinations carried out. Because precise epidemiological data only exists for new-onset 83 episodes in France, the statistical analysis was restricted to such episodes 5 . Importantly, such 84 analysis is based on the assumption that the probability of new-onset iTTP is uniformly 85 distributed and does not take into account ethnicity, gender, age or seasonal variation in iTTP 86 incidence. 87 88 Ten iTTP episodes occurring within 30 days after COVID-19 vaccination were reported, 89

including 7 new-onset iTTP episodes and 3 relapses. Clinical and biological characteristics of 90 patients are presented in table 1. Overall, these cases appear to be very similar to iTTP 91 episodes occurring outside the specific context of vaccination 1 : median age was 57 years, and 92 presenting symptoms were mostly neurologic (n=7; 70%). Cardiac involvement defined by 93 troponin elevation was seen in 7 patients (70%). Three patients (30%) had a history of systemic 94 autoimmune disease 6 . The clinical probability of severe ADAMTS13 deficiency was high in 95 most patients according to the French score with severe thrombocytopenia (platelets < 96 30x10 9 /L in n=8, 80%) and no/mild renal impairment (creatinine < 2.25 mg/dL in all, 100%) 6 . 97 TTP diagnosis was confirmed by measuring ADAMTS13 activity in all patients. The immune-98 mediated mechanism was confirmed by the demonstration of anti-ADAMTS13 autoantibodies 99 in 8 patients (80%) and the normalization of ADAMTS13 activity after the episode in all. 100 Importantly, the two patients who received an adenoviral vector-based vaccine tested 101 negative for anti-PF4 antibodies, excluding VITT 4,7 . 102

Treatment included therapeutic plasma exchange (n=8, 80%), anti-vWF therapy with 103 caplacizumab (n=7, 70%), and immunosuppression combining corticosteroids (n=10, 100%) 104 and frontline rituximab (n=8, 80%) according to the current standard of care 8 . One patient experienced exacerbation on-therapy but finally achieved clinical remission after 106 intensification with twice-daily therapeutic plasma exchange. Only one, heavily comorbid 70-107

year-old patient died two months after iTTP diagnosis from iTTP-related refractory status 108 epilepticus sequelae. At the time of death there was no feature of thrombotic 109 microangiopathy and the last available ADAMST13 activity was 74%. injection is broadly recommended, an important question is how to proceed with SARS-CoV-152 based on our experience, we recommend monitoring ADAMTS13 activity 13 . If the activity is 154 <20%, we recommend postponing the vaccination which could trigger a clinical relapse; pre-155 emptive rituximab treatment in case ADAMTS13 activity is <20% may still be recommended 14 . 156

If the activity is ≥20%, vaccination is probably safe. However, in patients who have received B-157 cell depleting therapies such as rituximab, the vaccine response is likely to be poor 15 . In such 158 patients, monitoring the vaccine response and/or providing additional doses could be useful. 159

In persistent non-responders, pre/post-exposure prophylaxis with therapeutic anti-SARS-Cov-160 2 antibodies can be considered. Table 1 . Clinical characteristics of immune-mediated thrombotic thrombocytopenic purpura episodes following COVID-19 vaccination * Due to the long delay since the last episode, these patients no longer had regular follow-up; consequently, no recent ADAMTS13 activity before vaccination is available. † Defined as above the upper limit of normal value. ‡ ADAMTS13 activity measurement was performed after initiation of immunosuppressive therapy. § The presence of anti-ADAMTS13 antibodies was assessed either as the titer of total autoantibodies (inhibitory and non-inhibitory) using an Enzyme-linked immunosorbent assay expressed in arbitrary units (U/mL; the value of at least 25 U/mL was considered positive); or as the titer of inhibitory antibodies using a Bethesda assay expressed in Bethesda Units (BU/mL) with one BU corresponding to the amount of inhibitor in 1 mL of plasma neutralizing 50% of ADAMTS13 activity of control levels (the value of at least 1.0 BU/mL was assumed to be positive). || In these two patients, TPE was omitted. Patient #8 was very comorbid and TPE was deemed too invasive. Hence, ADAMTS13 replacement was performed with plasma infusion only. In patient #10, initial presentation was a lupus flare with mild features of thrombotic microangiopathy. Initial treatment only included high dose corticosteroids, leading to a rapid improvement of both lupus symptoms and thrombocytopenia. Later, ADAMTS13 activity confirmed the diagnosis of iTTP and only plasma infusion was added to corticosteroids until complete remission 

Thrombotic thrombocytopenic purpura

Acquired thrombotic thrombocytopenic purpura: A 184 rare disease associated with BNT162b2 vaccine

Immune-mediated thrombotic 187 thrombocytopenic purpura following Pfizer-BioNTech COVID-19 vaccine

Insights in ChAdOx1 nCoV-19 vaccine-induced 190 immune thrombotic thrombocytopenia

Epidemiology and pathophysiology of adulthood-192 onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic 193 thrombocytopenic purpura): a cross-sectional analysis of the French national registry for 194 thrombotic microangiopathy

Predictive Features of Severe Acquired 196 ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA 197 Reference Center Experience

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 199 nCoV-19 Vaccination

ISTH guidelines for treatment of thrombotic 201 thrombocytopenic purpura

First report of COVID-19 vaccine induced flare of compensated 206 congenital thrombotic thrombocytopenic purpura

Clinical Features of Vaccine-Induced Immune 209 Thrombocytopenia and Thrombosis

Vaccine-induced immune thrombotic 211 thrombocytopenia (VITT): Update on diagnosis and management considering different 212 resources

Redefining outcomes in immune TTP: an international 214 working group consensus report

Humoral and cellular responses to mRNA 218 vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy 219